Primary cutaneous B-cell lymphomas – Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome

2008 ◽  
Vol 49 (6) ◽  
pp. 1094-1103 ◽  
Author(s):  
Philippa Golling ◽  
Antonio Cozzio ◽  
Reinhard Dummer ◽  
Lars French ◽  
Werner Kempf
Keyword(s):  
B Cell ◽  
Mycosis Fungoides ◽  
Classification System ◽  
Tnm Classification ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
B Cell Lymphomas ◽  
Cutaneous Lymphomas

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood ◽  
2007 ◽  
Vol 110 (2) ◽  
pp. 479-484 ◽  
Author(s):  
Youn H. Kim ◽  
Rein Willemze ◽  
Nicola Pimpinelli ◽  
Sean Whittaker ◽  
Elise A. Olsen ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
International Society ◽  
Classification System ◽  
Task Force ◽  
Tnm Classification ◽  
Cutaneous Lymphoma ◽  
Sézary Syndrome ◽  
European Organization ◽  
Tnm System ◽  
Cutaneous Lymphomas

Abstract Currently availabel staging systems for non-Hodgkin lymphomas are not useful for clinical staging classification of most primary cutaneous lymphomas. The tumor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sézary syndrome (SS) is not appropriate for other primary cutaneous lymphomas. A usable, unified staging system would improve the communication about the state of disease, selection of appropriate management, standardization of enrollment/response criteria in clinical trials, and collection/analysis of prospective survival data. Toward this goal, during the recent meetings of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), the representatives have established a consensus proposal of a TNM classification system applicable for all primary cutaneous lymphomas other than MF and SS. Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide.

Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome

2011 ◽  
Vol 38 (3) ◽  
pp. 295-297 ◽  
Author(s):  
Jonathan L. Curry ◽  
Victor G. Prieto ◽  
Dan M. Jones ◽  
Franscisco Vega ◽  
Madeleine Duvic ◽  
...  
Keyword(s):  
B Cell ◽  
Mycosis Fungoides ◽  
Lymphoproliferative Disorder ◽  
Sézary Syndrome ◽  
Sezary Syndrome

scholarly journals A novel lymphocyte differentiating factor in serum of patients with mycosis fungoides and Sezary syndrome

Blood ◽  
1979 ◽  
Vol 54 (4) ◽  
pp. 837-841
Author(s):  
B Safai ◽  
RA Good ◽  
JJ Twomey ◽  
V Lewis ◽  
G Goldstein
Keyword(s):  
Cell Differentiation ◽  
T Cell ◽  
B Cell ◽  
Mycosis Fungoides ◽  
Normal Serum ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
B Cell Differentiation ◽  
Lymphocyte Differentiation ◽  
Cell Series

Sera from 13 patients with mycosis fungoides and 2 with Sezary syndrome were tested for activity that induces lymphocyte differentiation. Induction of Thy-1.2 antigen and surface immunoglobulin were used, respectively, to measure T- and B-cell differentiation. The indicator cells were null lymphocytes from the spleens of congenitally athymic nude mice. Normal serum induced some T-cell but no B-cell differentiation. The T-cell-inducing activity was ascribed to thymic hormone and declined with advancing age. A totally different pattern emerged with patient serum. T-cell-inducing activity was significantly more active than in normal serum (p less than 0.001). This activity did not decline with advancing age and was not inhibited by a concentration of ubiquitin, which blocks nonspecific beta-adrenergic induction. B- cell-inducing activity was also present. This novel serum factor (or factors) is a potent inducer of T- and B-lymphocyte differentiation and is associated with neoplastic lymphoproliferation of the T-cell series.

scholarly journals A novel lymphocyte differentiating factor in serum of patients with mycosis fungoides and Sezary syndrome

Blood ◽  
1979 ◽  
Vol 54 (4) ◽  
pp. 837-841 ◽  
Author(s):  
B Safai ◽  
RA Good ◽  
JJ Twomey ◽  
V Lewis ◽  
G Goldstein
Keyword(s):  
Cell Differentiation ◽  
T Cell ◽  
B Cell ◽  
Mycosis Fungoides ◽  
Normal Serum ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
B Cell Differentiation ◽  
Lymphocyte Differentiation ◽  
Cell Series

Abstract Sera from 13 patients with mycosis fungoides and 2 with Sezary syndrome were tested for activity that induces lymphocyte differentiation. Induction of Thy-1.2 antigen and surface immunoglobulin were used, respectively, to measure T- and B-cell differentiation. The indicator cells were null lymphocytes from the spleens of congenitally athymic nude mice. Normal serum induced some T-cell but no B-cell differentiation. The T-cell-inducing activity was ascribed to thymic hormone and declined with advancing age. A totally different pattern emerged with patient serum. T-cell-inducing activity was significantly more active than in normal serum (p less than 0.001). This activity did not decline with advancing age and was not inhibited by a concentration of ubiquitin, which blocks nonspecific beta-adrenergic induction. B- cell-inducing activity was also present. This novel serum factor (or factors) is a potent inducer of T- and B-lymphocyte differentiation and is associated with neoplastic lymphoproliferation of the T-cell series.

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Blood ◽  
2007 ◽  
Vol 110 (6) ◽  
pp. 1713-1722 ◽  
Author(s):  
Elise Olsen ◽  
Eric Vonderheid ◽  
Nicola Pimpinelli ◽  
Rein Willemze ◽  
Youn Kim ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Cell Biology ◽  
Task Force ◽  
Prognostic Significance ◽  
Staging System ◽  
Cutaneous Lymphoma ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
European Organization ◽  
Cutaneous Lymphomas

Abstract The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.

Sign in / Sign up

Export Citation Format

Share Document